Incurin for Dogs: How Estriol Treats Hormone-Responsive Incontinence
Learn how Incurin (estriol) treats spay-related urinary incontinence in dogs — mechanism, dosing, side effects, efficacy data, and when to consult your vet.
Quick Answer: What Is Incurin for Dogs?
Incurin (estriol) is an FDA-approved prescription medication used to treat hormone-responsive urinary incontinence (also called urethral sphincter mechanism incompetence, or USMI) in spayed female dogs. It contains a short-acting estrogen that strengthens the urethral sphincter, reducing or eliminating involuntary urine leakage. Most dogs show improvement within 1–3 weeks of starting treatment, and approximately 75–90% of treated dogs achieve full continence at the individually titrated maintenance dose.
If you've noticed your dog leaving wet spots on her bed or the floor after sleeping, she's likely not misbehaving — she may have urinary incontinence. This condition is remarkably common in spayed females, affecting an estimated 5–20% of spayed dogs depending on breed and body size. Incurin is one of the two primary pharmaceutical options veterinarians reach for, alongside phenylpropanolamine (PPA/Proin). Understanding the science behind why this happens and how Incurin works at the physiological level will help you partner more effectively with your vet on treatment.
The Physiology Behind Hormone-Responsive Incontinence
How the Urethral Sphincter Normally Works
Urinary continence in dogs depends on a coordinated system: the detrusor muscle of the bladder wall, the internal and external urethral sphincters, and the neurological pathways that regulate them. The internal urethral sphincter — a ring of smooth muscle at the bladder neck — provides the primary resting tone that keeps urine from escaping between voluntary voids.
Estrogen plays a direct role in maintaining urethral sphincter tone through several mechanisms:
- Alpha-adrenergic receptor upregulation: Estrogen increases the sensitivity and density of alpha-adrenergic receptors in the urethral smooth muscle, enhancing the contractile response to sympathetic nerve signals.
- Collagen synthesis in periurethral tissue: Estrogen promotes collagen deposition in the connective tissue surrounding the urethra, improving the "seal" effect.
- Blood flow regulation: Estrogen maintains vascular engorgement of the urethral submucosa, which contributes to closure pressure — similar to how a pressurized gasket works.
- Mucosal thickness: Estrogen keeps the urethral epithelium thick and healthy, contributing to mechanical closure.
When a female dog is spayed (ovariohysterectomy), her ovaries — the primary source of circulating estrogen — are removed. Serum estrogen levels drop dramatically and permanently. For many dogs, this doesn't cause clinical problems. But in dogs with a predisposition (often related to breed, body size, or age at spay), the loss of estrogen's supportive effects on the urethral sphincter leads to urethral sphincter mechanism incompetence (USMI).
The result is involuntary leakage, most commonly observed when the dog is relaxed or asleep and gravity or increased abdominal pressure overcomes the weakened sphincter. This is why owners typically report finding wet spots on bedding rather than observing the dog actively urinating indoors.
Evolutionary Context: Why Estrogen Matters for Canine Continence
From Wolves to Companion Dogs
In wild canids — wolves, coyotes, and feral dogs — females remain reproductively intact throughout their lives. They experience seasonal estrus cycles (typically once or twice yearly) during which estrogen levels rise and fall, but they never undergo the sudden, permanent estrogen withdrawal that surgical spaying creates. In evolutionary terms, hormone-responsive incontinence essentially did not exist as a selective pressure in ancestral canid populations.
The domestication of dogs introduced artificial reproductive management, and widespread spaying — a practice that has enormous population control and cancer-prevention benefits — created a novel physiological scenario: a female dog living 10–15 years with near-zero circulating estrogen. The urethral sphincter's dependence on estrogen was never "designed" for this scenario. This is an iatrogenic condition — one created by a well-intentioned medical intervention — and it's why veterinary pharmaceutical science developed targeted solutions like Incurin.
How Incurin (Estriol) Works: The Pharmacological Mechanism
Incurin's active ingredient is estriol, one of the three naturally occurring estrogens in mammals (alongside estradiol and estrone). Estriol was specifically chosen for this indication because of its pharmacological profile:
- Short biological half-life: Estriol has a significantly shorter duration of action than estradiol. It binds to estrogen receptors but dissociates more rapidly, which reduces the risk of prolonged estrogenic stimulation to tissues like the bone marrow and reproductive tract.
- Preferential estrogen receptor-beta (ERβ) affinity: Estriol shows greater relative affinity for ERβ compared to ERα, which is relevant because ERβ is the predominant estrogen receptor subtype in the canine lower urinary tract.
- Targeted urethral effect: At therapeutic doses, estriol restores urethral sphincter tone by re-engaging the estrogen-dependent mechanisms described above — receptor upregulation, collagen support, and mucosal health — without producing the systemic effects associated with stronger, longer-acting estrogens.
According to the Merck Veterinary Manual, estriol is classified as a weak estrogen, which is precisely why it's suitable for long-term management of USMI: it provides enough estrogenic activity at the urethral sphincter to restore continence while minimizing the risks historically associated with estrogen therapy (bone marrow suppression, mammary tissue stimulation).
Dosing Protocol: Titration and Maintenance
Incurin is available as 1 mg scored tablets, and the dosing protocol follows a titration model — meaning your vet starts at a standard dose and adjusts based on your dog's response. This is critical: the goal is the lowest effective dose, not a fixed one-size-fits-all amount.
| Phase | Dose | Duration | Goal |
|---|---|---|---|
| Starting dose | 2 mg once daily (regardless of body weight) | 14 days | Assess initial response |
| If continent at day 14 | Reduce to 1 mg once daily | 7 days | Find minimum effective dose |
| If still continent | Reduce to 0.5 mg once daily | 7 days | Further dose minimization |
| If still continent | Reduce to 0.5 mg every other day | Ongoing | Lowest maintenance dose |
| If leakage returns at any step | Return to previous effective dose | Ongoing | Maintain continence |
Important: This table represents the standard manufacturer-recommended protocol. Your veterinarian may adjust the schedule based on your dog's individual response, concurrent conditions, and clinical judgment. Always follow your vet's specific dosing instructions.
The FDA-approved labeling for Incurin specifies that the maximum daily dose should not exceed 2 mg per day. In clinical field studies, the distribution of effective maintenance doses was approximately:
- ~15% of dogs maintained continence at 0.5 mg every other day
- ~25% at 0.5 mg daily
- ~30% at 1 mg daily
- ~30% required the full 2 mg daily
Efficacy Data: What the Research Shows
Incurin received FDA approval in 2011 based on field studies demonstrating safety and efficacy. Key findings from the pivotal clinical studies and subsequent research:
- Overall response rate: Approximately 83–92% of treated dogs achieved complete continence or significant improvement at their individually titrated dose.
- Time to response: Most dogs showed improvement within 7–14 days of starting treatment, with full continence typically achieved within 3 weeks.
- Long-term efficacy: In extended-use studies, dogs maintained continence on their established dose for the duration of treatment. Incontinence typically returns within days to weeks if treatment is discontinued.
- Non-responders: Approximately 8–17% of dogs do not respond adequately to estriol alone. These cases may require combination therapy with PPA, or investigation for alternative causes of incontinence such as ectopic ureters, urinary tract infection, or neurogenic bladder dysfunction.
A study published in the Journal of the American Veterinary Medical Association (Byron et al.) comparing estriol to PPA found both medications to be effective, with estriol showing comparable efficacy and a favorable side-effect profile for long-term use. You can review current prescribing information through the FDA's Center for Veterinary Medicine.
Side Effects and Safety Profile
Because estriol is a weak, short-acting estrogen, its side-effect profile is generally milder than older estrogen therapies (such as diethylstilbestrol/DES, which is no longer recommended for canine use due to bone marrow toxicity risks). However, side effects can occur, particularly at higher doses:
| Side Effect | Reported Frequency | Management |
|---|---|---|
| Vulvar swelling/enlargement | Common (~23%) | Usually resolves with dose reduction |
| Mammary gland enlargement | Occasional (~7%) | Monitor; dose adjustment |
| Attraction of male dogs | Occasional (~5%) | Separate from intact males |
| Decreased appetite | Uncommon (~3%) | Usually transient |
| Vomiting | Uncommon (~2%) | Give with food |
| Lethargy | Uncommon (~2%) | Monitor; consult vet if persistent |
Contraindications — When Incurin should NOT be used:
- Intact (unspayed) female dogs
- Male dogs (Incurin is approved for female dogs only)
- Dogs with known or suspected estrogen-sensitive tumors (e.g., certain mammary cancers)
- Dogs used for breeding
- Pregnant or lactating dogs
- Dogs with a history of bone marrow disorders (use with caution and veterinary monitoring)
⚠️ Veterinary Disclaimer: This information is for educational purposes. Incurin is a prescription medication that requires veterinary oversight. Always consult your veterinarian before starting, adjusting, or discontinuing any medication. Your vet will determine the appropriate dose and monitoring schedule based on your dog's complete medical history.
Incurin vs. PPA (Proin): How Do They Compare?
Phenylpropanolamine (PPA, sold as Proin) is the other first-line medication for USMI. Many owners ask which is "better" — the answer depends on the individual dog. Here's a direct comparison:
| Factor | Incurin (Estriol) | Proin (Phenylpropanolamine) |
|---|---|---|
| Mechanism | Estrogen receptor agonist — restores tissue health and receptor sensitivity | Alpha-adrenergic agonist — directly stimulates sphincter contraction |
| Approved for | Female dogs only | Male and female dogs |
| Efficacy rate | ~83–92% | ~74–90% |
| Dosing frequency | Once daily (may reduce to every other day) | Twice to three times daily |
| Common side effects | Vulvar swelling, mammary changes | Restlessness, irritability, increased blood pressure, tachycardia |
| Caution with | Estrogen-sensitive conditions | Hypertension, heart disease, kidney disease, hyperthyroidism |
| Approximate monthly cost (2026) | $25–$50 | $30–$60 |
Some dogs that don't respond fully to either medication alone achieve continence with combination therapy (Incurin + PPA at reduced doses), because the two drugs work through complementary mechanisms. Your veterinarian will guide this decision.
Breed Predispositions: Which Dogs Are Most Affected by USMI?
Research consistently shows that certain breeds are overrepresented in USMI cases, suggesting a genetic component to urethral sphincter competence. Larger breeds are disproportionately affected:
- Doberman Pinscher — among the highest reported prevalence
- Old English Sheepdog
- Rottweiler
- German Shepherd Dog
- Labrador Retriever
- Golden Retriever
- Weimaraner
- Irish Setter
- Boxer
- Siberian Husky
Dogs weighing over 45 lb (20 kg) are at significantly higher risk than smaller breeds. The exact genetic mechanism isn't fully mapped, but it likely involves inherited differences in urethral length, sphincter muscle mass, and estrogen receptor density in lower urinary tract tissues. The American Kennel Club notes that body size is one of the strongest predictive factors.
There is also evidence that age at spaying influences risk. Dogs spayed before their first estrus cycle (before ~6 months) may have slightly higher USMI rates than those spayed after reaching sexual maturity, because the urethral tissues never experienced estrogen-driven maturation. However, this must be weighed against the significant cancer-prevention benefits of early spaying — a conversation to have with your veterinarian, not a reason to delay spaying without professional guidance.
Common Misconceptions About Incurin and Incontinence
| Myth | Fact |
|---|---|
| "My dog is peeing in the house because she's mad at me or poorly trained." | USMI is involuntary — your dog has no conscious control over it. Punishment is counterproductive and damages your bond. She likely doesn't even realize she's leaking. |
| "Incurin is the same as giving my dog human hormone therapy — it's dangerous." | Estriol is a weak, short-acting estrogen specifically formulated and dosed for canine use. It is not equivalent to human HRT and has been FDA-approved for dogs with a well-characterized safety profile. |
| "Once she starts Incurin, she'll need it forever at the same dose." | Many dogs can be titrated down to a lower maintenance dose (even every other day). Some dogs — though a minority — experience spontaneous improvement and can discontinue treatment under veterinary guidance. |
| "Only old dogs get incontinence." | While prevalence increases with age, USMI can appear in dogs as young as 3–4 years old, particularly in predisposed large breeds. Onset is often within 2–4 years after spaying. |
| "I can just give my dog leftover human estrogen pills." | Never do this. Human estrogen products (estradiol, conjugated estrogens) are far more potent and carry serious risks for dogs, including life-threatening bone marrow suppression. Only use veterinary-prescribed Incurin at the directed dose. |
When Incontinence Signals a Bigger Problem
Not all urinary leakage is USMI. Your veterinarian will rule out other causes before prescribing Incurin. Seek prompt veterinary evaluation if your dog's incontinence is accompanied by any of these red flags:
🚨 Red Flags — See Your Vet Promptly
- Increased frequency of urination (pollakiuria) — may indicate UTI, bladder stones, or diabetes
- Blood in urine (hematuria) — could signal infection, stones, or neoplasia
- Straining to urinate (stranguria) — possible obstruction, which is an emergency
- Excessive thirst (polydipsia) alongside leakage — suggests systemic disease (diabetes, Cushing's, kidney disease)
- Incontinence in a male dog — Incurin is not approved for males; male incontinence requires different diagnostic workup
- Incontinence in a puppy — may indicate ectopic ureters, a congenital condition requiring surgical correction
- Neurological signs (hind limb weakness, tail drag) — may indicate spinal cord disease affecting bladder control
Your vet will typically perform a urinalysis, urine culture, and possibly imaging (ultrasound or radiographs) before confirming a USMI diagnosis. This diagnostic workup is essential — treating the wrong condition delays appropriate care.
Practical Tips for Living With a Dog on Incurin
Beyond medication management, here are evidence-based strategies to minimize the daily impact of USMI:
- Washable bedding: Use machine-washable blankets or waterproof bed covers. Many owners find that layering a waterproof liner under a soft, removable cover simplifies cleanup.
- More frequent walks: Increasing outdoor voiding opportunities (3–4 times daily instead of 2) reduces the volume of urine in the bladder at any given time, decreasing leakage episodes.
- Evening water management: Some owners remove water bowls 2–3 hours before bedtime to reduce overnight bladder filling. Discuss this with your vet first — it's not appropriate for dogs with kidney disease, diabetes, or other conditions requiring free-choice water access.
- Dog diapers or belly bands: For dogs with persistent leakage despite medication, washable dog diapers can protect furniture and flooring. This is a management tool, not a treatment.
- Monitor for UTIs: Dogs with USMI have a slightly increased risk of urinary tract infections because the weakened sphincter allows easier bacterial ascent into the bladder. Watch for changes in urination patterns and have your vet check a urine sample at least annually.
- Weight management: Excess body weight increases intra-abdominal pressure, which can worsen incontinence. Maintaining an ideal body condition score (BCS 4–5 on a 9-point scale) can reduce leakage severity.
Frequently Asked Questions
Is urinary incontinence in spayed dogs normal?
It's common, but not something to ignore. While 5–20% of spayed females develop USMI, any involuntary urine leakage warrants veterinary evaluation to confirm the cause and rule out more serious conditions. Once diagnosed as USMI, it's a manageable condition with a good prognosis.
Can male dogs take Incurin?
No. Incurin is FDA-approved only for female dogs. Male dogs can develop incontinence, but the causes and treatment approaches differ. PPA (Proin) is more commonly used for male dogs, and your vet will investigate for prostate disease, neurological issues, or other underlying causes.
How long does it take for Incurin to work?
Most dogs show noticeable improvement within 7–14 days of starting the initial 2 mg dose. Full continence is typically achieved within 3 weeks. If there's no improvement after 14 days at the starting dose, your vet will investigate alternative diagnoses or consider adding PPA.
Can I stop giving Incurin once my dog is continent?
Don't stop abruptly. During the titration protocol, your vet will gradually reduce the dose to find the minimum effective amount. Some dogs can maintain continence on very low doses (0.5 mg every other day). If you stop entirely and leakage returns, simply restart at the last effective dose and contact your vet. USMI is typically a lifelong condition requiring ongoing management.
Is Incurin the same as DES (diethylstilbestrol)?
No. DES is a synthetic, potent estrogen that was historically used off-label for canine incontinence but carries significant risks, including life-threatening bone marrow suppression (aplastic anemia). Incurin uses estriol — a naturally occurring, weak estrogen with a much wider safety margin. DES is no longer recommended for this indication when an FDA-approved alternative exists.
How does Incurin differ from how humans experience estrogen-related incontinence?
In humans, postmenopausal estrogen decline can also contribute to stress urinary incontinence, and topical estrogen therapy is sometimes used as part of treatment. The underlying mechanism — estrogen's role in maintaining urethral tissue integrity and sphincter tone — is remarkably similar across species. The key difference is that canine USMI is triggered by surgical removal of the ovaries (a sudden, total estrogen loss) rather than the gradual decline seen in human menopause, which is why the canine condition tends to be more pronounced relative to the dog's age.
What does it mean when my dog leaks urine only while sleeping?
This is the classic presentation of USMI. When your dog is awake and active, sympathetic nervous system tone and voluntary muscle engagement provide enough sphincter closure to prevent leakage. During sleep, these compensatory mechanisms relax, and the weakened sphincter can't maintain closure against bladder pressure — especially if the bladder is full. This positional pattern is a strong clinical indicator of sphincter incompetence rather than behavioral housebreaking issues or active UTI.
Cost and Access in 2026
Incurin is available by prescription from your veterinarian or through licensed veterinary pharmacies. As of 2026, typical costs include:
- Veterinary office visit + urinalysis (diagnostic workup): $120–$300 depending on your region and clinic type
- Incurin tablets (60-count bottle, 1 mg): $35–$65 through veterinary pharmacies
- Monthly medication cost at maintenance dose: $10–$35 depending on the titrated dose (lower maintenance doses = lower monthly cost)
- Annual recheck with urinalysis: $80–$200
Many pet insurance plans cover prescription medications like Incurin if the condition was not pre-existing. Check your policy's prescription drug coverage.
Key Takeaways
- Incurin (estriol) is a first-line, FDA-approved treatment for hormone-responsive urinary incontinence in spayed female dogs, with an 83–92% success rate.
- The mechanism is restorative: it replaces the estrogen that was lost when the ovaries were removed, rebuilding urethral sphincter tone through multiple physiological pathways.
- Dosing is individualized through a titration protocol — the goal is always the lowest effective dose.
- Side effects are generally mild and dose-dependent, resolving with dose reduction.
- USMI is not a behavioral problem — it's involuntary, and your dog cannot control it. Punishment is never appropriate.
- Always consult your veterinarian before starting, adjusting, or stopping Incurin. Proper diagnosis is essential to rule out other causes of incontinence.
Beth Carrasco
All our authors care for dogs every day — read more of their work on the authors page.
